Overview
Women's health company Hologic's fiscal Q4 rev grows 6.2% yr/yr, beating analyst expectations
Non-GAAP EPS for fiscal Q4 beats consensus, increasing 11.9%
Company to be acquired by Blackstone and TPG for up to $79 per share
Outlook
Company is not providing guidance due to acquisition by Blackstone and TPG
Result Drivers
DIAGNOSTICS GROWTH - Higher core U.S. molecular diagnostics sales drove diagnostics revenue growth, offset by lower COVID-19 assay sales and reduced sales in China
BREAST HEALTH - Growth driven by strong interventional product sales and improved U.S. sales execution
SURGICAL REVENUE - Increased sales of MyoSure and Fluent, and contributions from Gynesonics acquisition boosted surgical revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $1.04 bln | $1.03 bln (13 Analysts) |
Q4 Adjusted EPS | Beat | $1.13 | $1.10 (14 Analysts) |
Q4 EPS | $0.83 | ||
Q4 Adjusted Net Income | Beat | $254.70 mln | $246.10 mln (12 Analysts) |
Q4 Adjusted EBITDA | Beat | $347 mln | $346.05 mln (11 Analysts) |
Q4 Adjusted Gross Margin | 60.90% |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 15 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Hologic Inc is $75.50, about 2.1% above its October 31 closing price of $73.91
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nBw81t6qGa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)